Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 25%
Buy 20%
Hold 55%
Sell 0%
Strong Sell 0%

Bulls say

Incyte is a pharmaceutical company with a strong focus on developing small-molecule drugs. Their leading drug, Jakafi, is partnered with Novartis and treats rare blood cancers and graft versus host disease. Incyte also has a diverse portfolio of other marketed drugs and a promising pipeline in both oncology and dermatology. Despite risks such as slow market uptake and delays in approvals, their strong financials, experienced leadership team, and potential recurring benefit from Opzelura give us a positive outlook on the company's stock.

Bears say

Incyte is facing challenges and potential risks with their lead drug, Jakafi, approaching the end of its exclusivity in 2027 and facing competition from new and upcoming treatments. The company's pipeline is heavily focused on oncology and dermatology, which may limit their growth potential in other therapeutic areas. The positive CHMP opinion for their latest dermatology drug, Opzelura, may provide some growth opportunities in Europe, but it will take time to catch up to the US market. However, the company's valuation is high with an EV of ~$28B and a 12-month price objective of $140 per share, and any failures in their ongoing clinical programs could significantly impact their future revenue and financial success.

Incyte (INCY) has been analyzed by 20 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 20% recommend Buy, 55% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 20 analysts, Incyte (INCY) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $118.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $118.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.